FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial 1 Foundayo, Lilly's second FDA-approved obesity medicine, will be available via LillyDirect with free home delivery, starting at , with prescriptions accepted immediately and shipping beginning "People living with obesity need treatment options that meet them where they are and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment," said Supported by the rigorous ATTAIN clinical trial program, Foundayo was proven to help people lose weight and keep it off

While semaglutide is a GLP-1 agonist, tirzepatide is known as a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (GIP/GLP-1 agonist)
Tirzepatide-Specific Considerations Because tirzepatide has been available longer and studied in larger populations, its safety profile is better characterized
Additionally, glutathione converts darker eumelanin (found in pigmentation) into a lighter, yellowish form of melanin called pheomelanin, contributing further to a brightened skin effect